# Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

> **NCT00509496** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Skin Cancer
- Melanoma

## Interventions

- **DRUG:** fludarabine phosphate
- **DRUG:** cyclophosphamide
- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes
- **BIOLOGICAL:** autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes

## Key facts

- **NCT ID:** NCT00509496
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2011-07
- **Final completion:** 2012-07
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2013-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509496, "Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00509496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*